COVID-19 vaccines exhibits limited protection in blood cancer patients: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-04-24 02:45 GMT | Update On 2021-04-24 07:07 GMT

In a recent development, research has highlighted that mRNA COVID-19 vaccines may not fully protect people with the blood cancers, chronic lymphocytic leukemia ,(CLL) and multiple myeloma (MM).This was in accordance to two studies released late last week in Blood.

Because clinical trials of coronavirus vaccines didn't include people with blood cancers, who are prone to severe illness and complications, measuring their effectiveness in this population is important, the researchers said. They said a booster dose of the vaccine may be needed for CLL patients and that similar results would be expected for the Moderna vaccine, which they didn't test.

The first study found some interesting facts.

Only 39.5% of 167 Israelis studied who had CLL had a positive antibody-mediated response to the Pfizer/BioNTech COVID-19 vaccine, compared with 100% of 53 controls.CLL patients currently undergoing cancer treatment had significantly lower response rates to the vaccine than people who had completed treatment and were in remission (16% vs 79%).
Patients who hadn't yet begun treatment had a 55.5% immune response rate.
Likewise, people who had completed treatment at least 1 year before vaccination had a 94% response rate, compared with 50% among those undergoing treatment within the last year.

"Even though response rates were not optimal, patients with CLL should still get the vaccine and, if appropriate, it may be better to do so before CLL treatment starts although the disease itself may affect the response," lead author Yair Herishanu, MD, said in an American Society of Hematology news release.

The second study, from Greece, provided similar results after one dose of the Pfizer vaccine in older MM patients. Twenty-two days after the first dose of the vaccine, measurable neutralizing antibodies were found in 20.6% of 48 MM patients, compared with 32.5% of 104 healthy controls. Median patient age was 83.

Data analysis showed that of the MM patients, 72.9% were receiving chemotherapy, four were in remission and not receiving therapy, and nine had precancerous MM. The authors said that chemotherapy appears to blunt production of neutralizing antibodies after one vaccine dose and that older MM patients would need a second dose for a more robust immune response.

For the full article follow the link: American Society of Hematology news release

Primary source: Blood

Article Source : Blood

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Satabdi Saha

Dr Satabdi Saha (BDS, MDS) is a practicing pediatric dentist with a keen interest in new medical researches and updates. She has completed her BDS from North Bengal Dental College ,Darjeeling. Then she went on to secure an ALL INDIA NEET PG rank and completed her MDS from the first dental college in the country – Dr R. Ahmed Dental College and Hospital. She is currently attached to The Marwari Relief Society Hospital as a consultant along with private practice of 2 years. She has published scientific papers in national and international journals. Her strong passion of sharing knowledge with the medical fraternity has motivated her to be a part of Medical Dialogues.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

COVID-19 vaccines exhibits limited protection in blood cancer patients: Study

Similar News

Poor Oral Health Significantly Linked to Pre-Eclampsia in Pregnancy: Study

Home-Based Brain Stimulation Promising in Easing Fibromyalgia Symptoms: JAMA Study

Pramipexole Promising for Treatment-Resistant Depression, But Side Effects Remain a Concern: Study Suggests

Use of Vestibular Suppressants in Seniors with Dizziness Triples Fall Risk, Study Finds

Thyroid treatment may improve gut health in people with hypothyroidism: Study

Journal Club: GJMPBU Ft. Prof. Dr Vipul Yagnik, Executive Editor Dr. Sunny Duttagupta

Tirzepatide May Lower LDL Cholesterol in Adults, Systematic Review Finds

Metformin fails to Significantly Accelerate resolution of COVID-19 Symptoms in Low-Risk Adults: JAMA